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INTRODUCTION
The Arthropod-borne or arboviruses are a group of infectious agent 
that are transmitted by blood sucking arthropods from one vetebrate host 
to another.  Replication in the vertebrate host produces sufficient viremia 
that will  infect  other blood feeding arthropods.  The vector acquires a 
lifelong infection through ingestion of blood from a viremic vertebrate. 
The virus multiplies in the tissues of the arthropod without the evidence 
of  disease  or  damage.  Some  arboviruses  are  maintained  in  nature  by 
transovarian transmission in arthopods 75.
More  than  500  viruses  are  now  included  in  the  international 
catalogue  of  arboviruses.  Any  haemophagus  arthropod  can  serve  as  a 
vector of an arbrovirus.  Recognised vectors include mosquitoes, ticks, 
sand flies,  swallow bugs and possibly mites.   Except for urban yellow 
fever,  dengue  and  chikungunya  virus,  humans  are  typically  dead  end 
hosts  for  the viruses.   Generally  lower vertebrates such as avians and 
rodents serve as vertebrate hosts for a few of these viruses.  The major 
Arboviral  disease  world  wide  are  yellow  fever,  dengue,  Japanese 
Encephalitis,  St.  Louis  Encephalitis,  Western  Equine  Encephalitis, 
Eastern Equine Encephalitis, Russian spring summer encephalitis, West 
nile and Sand fly fever. 29 
Overview of Arbo viral infection:
Diseases  produced  by  arboviruses  may  be  divided  into  three 
clinical syndromes. 
1.  Fever  of  an  undifferentiated  type  with  or  without  a 
maculopapular rash and usually benign.  
2. Encephalitis often with high case fatality rate.  
3. Hamorrhagic fevers : frequently severe and fatal
Dengue Infection:
Global prevalence of dengue, an arbo viral mosquito borne disease, 
has  grown dramatically  in  recent  decades  giving rise  to  an  escalating 
public health problem.  In spite of extensive research done, many aspects 
of this disease remains obscure. Dealing with the uncontrolled expansion 
of dengue infection continues to pose a challenge. The first clinical report 
of dengue is attributed to Benjamin Rusk who coined the term ‘ break 
bone fever ’ during the philedelpia epidemic in 1780.  Dengue epidemics 
were  reported  through  out  the  19th and  20th centuries  in  Americas, 
Southern  Europe,  North  Africa,  The  Eastern  Mediterranean,  Asia  and 
Australia and various islands in the Indian Ocean, The south and central 
pacific and the Caribbean. Dengue fever (DF) or Dengue haemorrhagic 
fever  (DHF)  and  have  steadily  increased  in  both  incidence  and 
distribution over the past 40 years.  Annually it is estimated that there are 
20 million cases of dengue infections resulting in around 24,000 deaths 64. 
During the 1960s and 1970s, DHF/DSS progressively increased as 
a health problem, spreading from its primary location in major cities to 
smaller cities and towns in endemic countries. In many countries, Dengue 
fever and Dengue haemorrhagic fever are primarily a disease of children, 
since they represent the largest segment of susceptible individuals with 
the population at risk 76.
In India,  dengue fever has been documented from the early part of 
last century.  The virus was first isolated in Kolkatta in 1945.  All four 
dengue sero types are present in India.  In 1988,  some cases of DHF 
were  seen  for  the  first  time  in  children  in  Delhi.   The  first  culture 
confirmed extensive epidemic of DHF, affected Delhi and adjoining areas 
during 1966.  This was caused by DEN – 2 and affected mostly 5 to 20 
years age group. India was affected by a much more wide spread dengue 
epidemic in 2003.  During this epidemic, the most affected age group was 
21 – 30 years.  DHF is now a significant public health problem in most of 
the countries in the tropical areas of the South – East Asia and Western 
Pacific  Regions.  The  disease  is  among  the  ten  leading  cause  of 
hospitalization  and  death  in  children  in  at  least  eight  tropical  Asian 
countries 14, 30. 
The Dengue Viruses
Dengue  virus  belongs  to  the  family  Flaviviridae.  The  four 
serotypes  of  dengue  virus  (designed  DEN-1,  DEN-2,  DEN-3,  DEN-4 
etc.,) can be distinguished by serological methods. Infection in humans 
by one serotype produces life-long immunity against reinfection by that 
same serotype, but only temporary and partial protection against the other 
serotypes. They posses a single stranded, non segmented positive sense 
RNA  approximately  11Kb  long  surrounded  by  an  icosahedral 
nucleocapsid and covered by a lipid envelope. The size range from 37 – 
50 nm in diameter.  The genome is unfragmented.  The RNA has 5’ cap 
but lacks a Poly A 3’ tail.   The mature virion consists of 3 structural 
proteins – core (c), membrane associated (M) and envelope (E)  and 7 
non structural proteins. NSI (associates with infected cell’s membrane), 
NS2a,  NS2b,  NS3  (perinuclear  localization),  NS4a,  NS4b,  and  NS5 
(RNA  dependent  RNA  polymerase).  The  envelope  glycoprotein  is 
involved  in  the  main  biological  function  of  the  virus,  it  binds  to  the 
receptors on the host cells, allowing the virus to be transported through it. 
It  is  also associated  with Haemagglutination,  induction of  neutralizing 
antibodies  and  protective  immune  response.  The  order  of  proteins 
encoded is  5’-C-prM(M)-E-NSI-NS2A-NS2B-NS3-NS4A-NS4B-NS4B-
NS5-3’. Different strains of dengue virus may differ in their virulence in 
their pathogenic and epidemic potential 49, 76.  
Transmission of Dengue viruses
Dengue  viruses  are  transmitted  to  humans  through  the  bite  of 
infected  mosquitoes  principally  by  the  bite  of  Aedes  aegypti.   Once 
infected, the mosquitoes remain infected life long, transmitting the virus 
to susceptible individuals. Transovarian transmission can also occur.  The 
viruses are known to cause infection only in humans 22.
The vector
Aedes aegypti (Ae. aegypti) is a tropical and subtropical species of 
mosquito  found around the globe,  usually  between latitudes  35oN and 
35oS,  approximately  corresponding  to  a  winter  isotherm  of  10oC. 
Although  Aedes  aegypti  has  been  found  as  far  north  as  45oN,  such 
invasions  have  occurred  during the  warm season,  and  the  mosquitoes 
have not survived the winters.  Distribution of Ae. aegypti is also limited 
by altitude.  It is usually not found above 1000m but has been reported at 
2121m in India. Ae. aegypti is one of the most efficient mosquito vectors 
for arboviruses, because it is highly anthropophilic and thrives in close 
proximity to humans and often lives indoors. The female mosquitoes bite 
humans during the day. The virus multiplies in the salivary gland and 
when the mosquito bites humans for food the virus is injected into the 
host. Once infected,  the mosquito hosts remain infective for life.  Dengue 
outbreaks have also been attributed to Ae. albopictus, Ae. polynesiensis 
and several species of the Ae. scutellaris complex.  Each of these species 
has its own particular geographical distribution; however, they are less 
efficient  epidemic  vectors  than  Ae.  aegypti.   While  vertical  (possibly 
transovarian) transmission of dengue viruses has been demonstrated in 
both the laboratory and the field, the significance of this to maintenance 
of the virus has not been established.  A factor complicating eradication 
of  the  vector  is  that  Ae.  aegypti  egg  can  withstand  long  periods  of 
desiccation, sometimes for more than a year 76.
The host
In  humans  each  of  the  four  dengue  virus  serotypes  has  been 
associated with DF and with DHF/DSS.  DSS occurs frequently in two 
immunologically  defined  groups,  children  who  have  experienced  a 
previous  dengue infection  and infants  with wanning level  of  maternal 
dengue antibodies. The acute phase of infection follows an incubation of 
3-14 days, lasts for 5-7 days and is followed by an immune response 9, 76.
Pathogenesis
Most primary infections are clinically silent.  Dengue fever though 
debilitating is mostly self limiting.  DHF and DSS occur more frequently 
due to sequential  infection in person sensitized by prior exposure to a 
different serotype of dengue virus.  The risk factors for DHF include the 
strain and serotype of the infectious virus, as well as the age, immune 
status  and  genetic  predisposition  of  the  patient.  Case  fatality  and 
hospitalization rates due to DHF/DSS are highest in infants and elderly. 
DHF is  distinguished  from DF by  the  presence  of  increased  vascular 
permeability.  The  targets  for  dengue virus  replication  are  the  cells  of 
monocytes / macrophage lineage that bear Fc receptors(FcRs).  In those 
who had previous infection with heterologus dengue virus serotype, the 
secondary  infection  results  in  the  production  of  non-protective  (non-
neutralizing) IgG antibodies that bind to the virion surface and through 
interaction with the Fc receptors, focus secondary dengue viruses on the 
target cell the result being enhanced infection.  Due to similar antibody 
dependant enhancement (ADE), children in their first year of life who had 
acquired maternal Antibody with ADE characteristics, may develop DHF 
with  primary  infection.   Activation  of  complement  with  profound 
depression  of  C3 &  C5 is  a  constant  finding  in  DHF/DSS.   T  cells 
response,  especially  that  of  cross  reactive  T  cells  play  a  role  in  the 
pathogenesis  of  DHF.   The  rapid  release  of  cytokines  and  chemical 
mediators caused by T cell activation and lysis of infected monocytes, 
directly affects vascular endothelial cells resulting in plasma leakage and 
hemorrhage.  Interferon Gamma up regulates expression of FC receptors 
and thereby increase antibody dependent enhancement of dengue virus 
replication.
Platelet defects may be both qualitative and quantitative, i.e. some 
circulating  platelets  during  acute  phase  of  DHF  may  be  exhausted 
(incapable of normal function).  Therefore even a patient with a platelet 
count > 1,00,000 still have a prolonged bleeding time 69, 12.
Internal organs
Liver: Focal necrosis of hepatic cells, swelling, appearance 
of 
                               councilman bodies and hyaline necrosis of kupffer cells.
Bone Marrow: Depression of  all  hematopoietic  cells  was  
observed 
                                           which would rapidly improve as fever subsided 
Kidney: Mild immune complex type of Glomerulo nephritis
Skin:  Perivascular Oedema of the terminal micro vasculature of 
dermal  papillae  and  infiltration  of  lymphocytes  and 
monocytes.  Deposition  of  serum  complement,  IgG, 
fibrinogen  in vessel wall has also been described 76.
Manifestations of Dengue virus infection
Dengue Virus Infection
Asymptomatic Symptomatic
       
                    Undifferentiated fever   Dengue fever syndrome     Dengue haemorrhagic 
                      (viral syndrome)                                                     fever (plasma leakage)
                                  without haemorrhage    with unusual   No shock    Dengue shock 
                                                                       haemorrhage                         syndrome 
  
 Dengue fever                          Dengue 
                                       haemorrhagic fever  
   
 Dengue Fever:  
Clinical pictures depends on the age of the patient.  Infants and 
young  children  may  have  indifferent  febrile  illness  with  rash.  Older 
children and adults have mild febrile illness or fever of abrupt onset with 
2 peaks., saddle back type of fever, severe headache, pain behind eyes, 
muscle  and  bone  or  joint  pains,  nausea  and  vomiting  and  rash. 
Leukopenia and thrombocytopenia may be observed
   Dengue Haemorrhagic Fever 
Characterised  by  four  major  clinical  manifestation.  High  fever, 
haemorrhagic  phenomenon  and  often    hepatomegaly  and  circulatory 
failure. Major patho physiological changes that determine the severity of 
the disease in DHF and DF is leakage of plasma, manifested as elevated 
haematocrit, a serous effusion or hypoproteinemia. Clinical presentation 
is  characterized  by  sudden  rise  in  temperature  accompanied  by  facial 
flush, anorexia, vomiting, headache, muscle or bone and joint pain.
Signs: positive tourniquet test, mild hepatomegaly 28 
Dengue Shock Syndrome 
The  condition  of  patients  who  progress  to  shock  suddenly 
deteriorates after fever of 2-7 days’ duration.  DSS is characterized by 
weak pulse with narrowing of pulse pressure and becomes fatal  if  not 
managed appropriately. Pleural effusion and ascites may be detected by 
physical  examination  and radiography.   Convalescence  in  patient  with 
corrected Dengue Shock Syndrome is short  and uneventful.  Course of 
DHF is approximately 7-10 days 76.
Serological diagnosis depends on the presence of IgM antibody or 
a rise in IgG antibody titre in paired acute and convalescent phase sera. 
IgM antibody becomes detectable during the acute phase of illness and 
90%  of  patients  are  IgM  positive  by  the  sixth  day  after  onset  of 
symptoms.  This antibody may be detectable for a median of about 60 
days.   Currently  the  most  widely  used  IgM  assay  is  capture  ELISA 
(Enzyme Linked Immuno Sorbant Assay) 7. 
Diagnostic approach
Detection of dengue virus by culture is the definitive diagnostic 
test,  but  practical  consideration  limits  its  use.   Rate  of  virus isolation 
significantly improves in those samples collected within 6 days after the 
onset of disease.  
Four isolation systems are routinely used 76   
1.   Intracerebral  inoculation into  1-3  days  old  suckling  mice, 
mammalian cell cultures,   inoculation  of mosquito adult / larvae and 
use of mosquito cell culture.
       2. Detection of viral antigens 
Dengue  viral  antigen  may  be  detected  in  acute  sera  and  in 
peripheral blood mononuclear cells especially during febrile phase of 
illness.   Antigen capture ELISA (Enzyme Linked Immuno Sorbent 
Assay) and IFA technique have been recommended for use.
3. Detection of Viral Nucleic Acid
 PCR based techniques
 Hybridization probes detects viral nucleic acid with 
cloned hybridized probes.
RT-PCR amplification may provide a rapid serotype specific 
diagnosis. This method is rapid, simple and can be used for 
detection of viral RNA in human clinical samples, autopsy 
tissues or mosquitoes.
4. Serology
Less specific than isolation of viruses
a. ELISA – Dengue specific IgM or IgG ELISA
b. HAI – Heam agglutination Inhibition  
c. NT – Neutralization Test
d. CFT – Complement Fixation Test
Management
Dengue fever:  
          Supportive - Bed rest during febrile period, antipyretic, electrolyte, 
fluid replacement if there is vomiting, sweating, thirst or diarrhea.
Degnue Haemorrhagic Fever / Dengue Shock Syndrome:
Immediate  evaluation  of  vital  signs  and  the  degree  of  haemo 
concentration, dehydration and electrolyte imbalance.
Blood transfusion /  transfusion of platelets – if there is bleeding.
Prevention of Dengue Infection
A. Vector Control 
I. Antilarval Measure
a. Environmental Control
b. Chemical control
c. Biological control
II. Anti adult measures
1. Residual sprays
2. Space sprays
     3. Genetic control
III. Protection against Mosquito bites
 
a. Mosquito Net
b. Repellents       
B. Dengue Vaccines 69
Approaches towards development of Dengue Vaccines
The following technologies were attempted to develop a vaccine against 
dengue
1. Live attenuated Tissue Culture Vaccine
2. Infectious clone technology
3. Synthesis of subunit vaccines
4. Alternative biotechnological based dengue vaccine candidates
Economic aspect of dengue 
Children  most  frequently  suffer  from  DHF/DSS  with  average 
hospital  stay  involves  5-10  days  for  severe  cases.   Intensive  care  is 
needed for severely ill patients.  There is both direct and indirect costs for 
each dengue patients ranging from inconvenience to substantial cost for 
hospitalization and disruption of earning potential 76.
AIM AND OBJECTIVE OF THE STUDY
1. To  study  the  epidemiology  of  Dengue  in  Madurai  by 
screening  the  suspected  Dengue  cases  admitted  at 
Government Rajaji Hospital, Madurai.
2. To study the sero prevalence of Dengue infection in these 
cases by subjecting the serum samples to IgM / IgG spot 
ELISA and IgM capture ELISA.
3. To isolate the Dengue virus from the IgM positive samples 
by inoculating into the suckling mice.  
4. To confirm the presence of Dengue antigen in the brain of 
suckling mice by haemagglutination (HA) technique.  
5. To  confirm  the  presence  of  Dengue  virus  in  the  brain 
isolates by subjecting to RT-PCR. 
6. To  find  the  type  of  the  Dengue  virus  by  single  tube 
multiplex PCR by sero type specific amplicons. 
REVIEW OF LITERATURE
Dengue  fever  and  especially  the  more  severe  manifestation, 
Dengue  haemorrhagic  fever,  ranks  highly  among  new  and  newly 
emerging  infectious  disease  in  public  health  significance  and  is 
considered  to  be  the  most  important  of  all  the  arthropod  borne  viral 
diseases  ( WHO – 1997) 76.
Most  arboviruses  are  maintained  in  nature  in  cycles  involving 
preferred hematophagous arthropod vectors  and vertebrate  hosts.   The 
amplifying  vertebrate  host  develops  viremia  of  sufficient  titer  and 
duration to infect additional feeding vector species (Watts et al 1973) 75.
We owe to Benjamin Rush the first to describe the accurate clinical 
description  of  the  dengue  fever  as  is  occurred  during  Philadelphia 
epidemic of 1780 (Siler et al 1926 and Carey 1971) 66,10 .
Schlesinger 1977  64 in his article mentioned that during 19th and 
20th centuries extensive outbreaks were reported from tropical  and sub 
tropical areas on all continents and from many sub continents and islands 
in the south pacific and Caribbean.
Gubler  1998  27 stated  that  Dengue  was  a  major  public  health 
problem  globally.   Manifested  clinically  in  two  forms  viz.  Dengue 
Heamorrhagic  Fever  (DHF)  and  Dengue  Shock  Syndromes  (DSS), 
leading to serious public health problem exacting heavy morbidity and 
mortality every year.
WHO 1997  76 states  that,  this  mosquito  borne  disease  was  the 
dreadful infectious disease after malaria, with an estimated 100 million 
cases of DF, 50,000 cases of DHF and 2,50,500 deaths annually.
By 1997 most of the countries of SEARO  had experienced large 
out breaks of the disease, currently DF/DHF is endemic in Bangaladesh, 
India,  Indonesia,  Maldives,  Myanmar,  Srilanka  and  Thailand. 
Approximately  1.3  billion  people  are  living  in  the  endemic  areas. 
Dengue Fever / Dengue Haemorrhagic Fever is widely prevalent in India 
and all the 4 sero types are found in the country.  It is reported from 15 
States / Union Territories since 1996.  During 2003, there were 12750 
cases with 217 deaths from dengue in the country. [Government of India 
2004,24 Annual  report  2003-2004,  Ministry  of  Health  and  Family 
Welfare, New Delhi].
In  Southern  India,  Dengue  was  mainly  an  urban  disease  in  the 
1960’s  and  1970’s  associated  with  the  container  breeding  vectors  of 
Aedes aegypti.  Many isolations of all the four sero types of dengue virus 
were made from pools of Aedes aegypti. During that time, there was little 
storage of water in villages and therefore Aedes species were scarce and 
dengue was absent in rural areas. Subsequently with the introduction of 
piped water supply, dengue made incursions to the rural areas of South 
India and outbreaks have been reported. [Carey et al., 1964 and Abdul 
Kader et al, 1997 9, 1 ]    
Rosen L. 1999  60 in his article mentioned that demographic and 
societal  changes  such  as  population  growth,  urbanization  and  modern 
transportation  contributed  greatly  to  the  increased  incidence  and 
geographic spread of dengue activity.
Gubler  D.J.  2002  29 in  his  study  stated  that  the  current 
epidemiologic situation in Latin America resembled that in South East 
Asia some years ago with co circulation of multiple serotypes in many 
countries and increased number  of DF and DHF cases.   During 2002, 
Latin American countries reported 71 million cases of DF with 7,17,000 
cases of DHF including 225 deaths.
Guzman and Kouri 2002  33 in their  article  stated that,  Dengue 
Virus was a mosquito borne flavivirus with 4 sero types DEN1, DEN2, 
DEN3 and DEN4. Dengue had been found in more than 100 countries 
and 2.5 billion people lived in areas where dengue was endemic.  Fifty to 
one hundred million cases of dengue infection were estimated to occur 
annually.  Dengue caused by four sero types of Dengue virus was the 
most prevalent arthropod borne illness in humans ranging from the DF to 
DHF/DSS. 
WHO,  Dengue  Haemorrhagic  Fever  1997  76 stated  that  the 
clinical  features  and  severity  of  dengue  infection  was  frequently 
influenced by the age and genetic make up of the host, the sero type of 
the infecting virus and the prior history of dengue infection of the host.
Dengue virus is a positive stranded encapsulated RNA virus. The 
Genomic RNA is approximately 11Kb in length and is composed of three 
structural protein genes that encode and nucleocapsid or core protein (C), 
a  membrane  associated  protein  (M)  and  an  Envelope  protein  (E)  and 
seven non structural proteins. [Malaviga G N et al 2004] 49
Burke et al  1988, Halstead S B et al  2002  7,  35 in their  article 
stated that the proteins were synthesized as a polyprotein of about 3000 
amino acids that was proceeded contranslationally and posttranslationally 
by viral and host  proteases.   There were four distinct  sero types,  sero 
types 1 – 4.  Infection induced a life  long protective immunity to the 
homologus sero types but conferred only partial and transient protections 
against subsequent infection by other sero types.  Instead, it had generally 
been accepted  that  secondary  infection  or  infection  with secondary  or 
multiple infections with various dengue virus sero type was a major risk 
factor for DHF/DSS due to antibody dependent enhancement.
Thakara  J.P. et  al 2004 72 in  their  study  found  concurrent 
infection with more than one sero type.
Srivastra et al  68 in his study mentioned that, the distribution of 
DHF and DSS in Asia had been particularly puzzling.  Before 1989, DHF 
was  common  in  South  East  Asia  but  rare  in  the  Indian  subcontinent, 
despite the circulation of all four serotypes in both regions.  After 1989, 
this pattern of disease had changed and regular epidemics of DHF were 
reported from several countries in the Indian sub-continent.
WHO 1999 77, referred Dengue that was an endemic viral disease 
affecting  tropical  and  sub  tropical  regions  around  the  world 
predominantly  in  urban  and  semi  urban  areas.   Dengue  fever  and  its 
severe forms, Dengue haemorrhagic fever and Dengue Shock Syndrome 
were  becoming  important  public  health  problems  and  were  formally 
included within the disease port folio of the UNDP / World Bank / WHO 
special programme for Research and Training in tropical diseases by the 
joint co-ordination Board in June 1999.
Susan Shepherd et al 71 states that transmission of Dengue is by 
the bite of infected female Aedes mosquitoes (Extrinsic Incubation period 
8-10 days).   The main vectors are Aedes aegypti (a container breeding 
day biting mosquito) and Aedes albopictus.  Humans and mosquitoes are 
the principal host of dengue virus. The mosquitoes remain infected for 
life.  The viruses are known to cause illness only in humans.  In the rain 
forests of Africa and Asia the virus is probably sustained through vertical 
(transovarial) transmission in the mosquito with periodic amplification in 
non- human primates.
Joshi  et  al  2002  42 in  his  article  described  that  experimentally 
transovarial transmission had been shown in Aedes aegypti.  Mosquitoes 
and  these  vector  mosquitoes  also  played  an  important  role  in  the 
maintenance of the virus in nature.
Gupta E et al 2005 30 in his article mentioned that the epidemic of 
2005 in Delhi involved the age group of 21-30 yrs. The author concluded 
that  the  intensive  mosquito  elimination  programme  after  the  1996 
epidemics,  might  have  shifted  the  mosquito  population  towards  non 
residential areas and there by infected mobile working population of the 
higher age group.
Mahadev P V M et al, 2004 NIV Pune 48  also had found Aedes 
aegypti as the vector in Maharashtra.
Sumodan et al 2003  70, and Hiriyan J. Tewari et al 40  in their 
Vector  surveys  carried  out  at  Ernakulam  and  Kozhikode  airport, 
identified Aedes albopictus as the vector. 
Dengue  fever  is  characterized  by  fever  for  3-5  days  duration, 
headache,  muscle  and joint  pain and a  rash,  which is self-limited  and 
from which patients  usually  recover  completely.   There is  no specific 
treatment  for  DF and most  forms of  therapy are  supportive in nature. 
DHF/DSS is characterized by the same signs and symptoms as classic 
DF,  but  it  is  followed  by  increased  vascular  permeability  and 
haemmorhage which may lead to vascular collapse and death (Burke et 
al 1988 7)
Rita  Maria  Riberio  Nogueira  et  al  2002  59 have  conducted  a 
study involving 1559 cases  with febrile  illness.   The symptoms  noted 
were headache, retrobulbar pain, myalgia, arthrlgia, rash and hemorrhagic 
manifestation.
The Text Book of  Harrisons, Principles of Internal Medicine 39, 
state that Dengue virus infection may be asymptomatic or may give rise 
to  broad spectrum of  effects  such  as  undifferentiated  fever,  DHF and 
DSS.   Patient  with  Dengue  haemorrhagic  fever  have  high  fever, 
haemorrhagic  manifestation,  hepatomegaly  and  circulatory  failure. 
Thrombocytopenia and haemoconcentration are constant features.  Rare 
presentations  includes  cardiomyopathy,  fulminant  hepatic  failure  and 
unusual neurological presentation.  
Once inoculated into the human host,  dengue has an incubation 
period of 3-14 days.  Following incubation  for  about 5-7, days acute 
febrile illness ensues.  Recovery is usually complete by 7-10 days. DHF 
or  DSS  usually  develops  around  the  third  to  seventh  day  of  illness, 
approximately at the time of defervesence. The major pathophysiological 
abnormalities  that  occur  in  DHF  and  DSS  are  plasma  leakage  and 
bleeding.  Plasma leakage is caused by increased capillary permeability 
and  may  be  manifested  by  haemoconcentration,  as  well  as  pleural 
effusion  and  ascites.   Bleeding  is  caused  by  capillary  fragility  and 
thrombocytopenia  and  may  present  in  various  ways,  ranging  from 
petechial  skin  hemorrhage to  life  threatening gastrointestinal  bleeding. 
Most patients who develop DHF or DSS have had prior infection with 
one or more dengue serotype. 
Philip Samuel et al  55 in an epidemic investigation reported that 
100%  cases  presented  with  fever  (83.3%),  myalgia  (70%),  arthralgia 
(56.7%), headache (6.7%) and retro orbital pain (6.7%).
Gadia R R et al 2002 21 in his study found that 87% patients had 
headache, 83% body ache, 74% vomiting, 47% arthralgia, 40% bleeding, 
38% Rhinitis, 38% abdominal pain, 25% anorexia, 20% diarrhoea, 16% 
cough, 8% Vertigo,  4% Seizures and 3% coma. 
Ramamurty N. et al 2004 56 stated that among 78 cases presented 
as  dengue  fever,  21  cases  presented  with  neurological  symptoms  of 
altered consciousness, Convulsions and seizures.
Manoj Kumar et al 2005 51 found in his studies that the serotypes 
responsible for the Delhi outbreak were serotype 2 & 3.  Most of the 
cases were presented with DF and sporadic cases with DHF
Malaviga G.N et al 2004  49 in his study stated that annually an 
estimated  100  million  cases  of  DF  and  half  a  million  cases  of  DHF 
occured in the world with a case fatality of 0.5-3.5 % in Asian countries. 
90% of DHF subjects were children under 15 yrs of age
Dar L, et al 14 in his studies stated that epidemics of DHF in Delhi, 
in 1996 affected mainly 5-20 yrs age group.
At present, the three basic methods used by most laboratories for 
the  diagnosis  of  dengue  virus  infection  are  viral  isolation  and 
characterization,  detection  of  the  genomic  sequence  by  Nucleic  Acid 
amplification  technology  assay  and  detection  of  dengue  virus  specific 
antibodies. After the onset of illness, virus is found in serum or plasma, 
circulating  blood cell  and selected  tissues  for  approximately  2-7  days 
(WHO – 1997 76).
Molecular diagnosis based on RT-PCR such as one step or nested 
PCR  or  Nucleic  Acid  Sequence  Based  Amplification  (NASBA)  has 
greatly replaced virus isolation, as the new standard for the detection of 
dengue virus in acute phase serum sample. For acute and convalescent 
phase sera, serological detection of antibodies based on capture 1gM & 
1gG ELISA has become the new standard for the detection of primary 
and secondary dengue virus infection. [Gubler.D.J. 1997 26, Innis B.L. et 
al 1989 41]
Lanciotti R.S. et al 1992  47 and Rosario D et al 1998  61 in his 
article described that Polymerase Chain Reaction (PCR) had been applied 
to  dengue diagnosis  with sera,  tissue  from fatal  cases,  mosquito pool, 
infected cell cultures and mosquito larvae.  Several PCR protocols for 
dengue detection had been described that  vary  in  the  RNA extraction 
methods,  genomic  location  of  primers,  specificity,  sensitivity  and 
methods to detect PCR products and to determine the sero types.  Reverse 
Transcriptase-Polymerase Chain Reactions had been provided to be one 
of the most important steps in the molecular diagnosis of dengue virus.  A 
rapid assay had been developed followed by a second PCR with specific 
primers  allowing  sero  type  identification  (DNA products)  of  different 
sizes according to the dengue sero type obtained. Virus isolation by cell 
culture  and  from mosquitoes  remain  the  gold  standard,  but  has  been 
replaced by RT PCR method for rapid diagnosis.
 Oliveria  D.P.S  et  al  2003  53 has  showed  that  the  molecular 
method  based  on  RT-PCR  had  been  combined  with  the  cell  culture 
methods to improve the sensitivity and reduce the time needed to identify 
the cultured virus studies.
The field of molecular diagnosis has changed significantly over the 
past  decades  leading  to  assays  that  are  much  more  reliable  for  the 
detection and characterization of various pathogens. Several protocols are 
available  among  these.  The  two steps  multiplex    RT PCR protocols 
originally reported by  Lanciotti et al (1992)  47 and later modified to a 
single  step  multiplex  RT-PCR for  the detection and typing of  dengue 
virus by  Harris et al (1998)  37 are well known. These assays used the 
dengue virus  core  to  pre  membrane  region as  the  target  sequence  for 
dengue  virus  detection.  They  had  the  advantage  of  detecting  and 
differentiating the four dengue virus serotypes analyzing the unique size 
of the amplicons in the agarose gel.
Domingo et al 2004 18 in his study using RT nested PCR on 167 
samples from febrile illness diagnosed classical dengue fever by WHO 
criteria. Sixteen of these cases were found positive by RT nested PCR, all 
the serum sample were collected during the first week after the onset of 
symptoms.
Manoj Kumar et al, NICD New Delhi 2003 51 studied 32 serum 
samples from clinically suspected cases of DF/DHF.  Tested by RT-PCR, 
7  were  positive,   yielded  amplification  of  511bp  C-PreM  region  of 
dengue  virus.  Further  studies  revealed  that  among  the  7  isolates,  5 
belonged to dengue-type 3 and 2 belonged to dengue type 2.
Soundravally R and Hoti S L, Pondicherry 2004 67 Studied 129 
samples  from  suspected  dengue  cases.  RT-PCR  was  done,  for  forty 
positive cases.  Fourteen samples yielded amplicon for the size of 290 bp, 
diagnostic of dengue sero type 3.
Guzman  M.G  et  al (1996) 32 explained  the  uses  of  cultured 
mosquito  cells  such  as  Ap61,  C6/36  cells,  vero  and  BHK2  cells  in 
Dengue diagnosis.
Dash PK Saxena, D R & D Gwalior 2003 15 showed isolation of 
virus from RT PCR samples, in day old suckling mouse as well as C6/36 
cells 
Several methods have been described for the serological detection 
of  dengue  viruses  including  haemaggutination,  neutralization  test, 
indirect  immuno  fluorescence,  ELISA,  Compliment  Fixation  Test,  dot 
blotting,  western  blotting  and  rapid  immuno  chromatography  test. 
Among  these  capture  IgM  /  IgG  ELISA  and  antigen  coated  indirect 
IgM/IgG ELISA are commonly used.
Branch S.L. et al 1999 5 & Lam S.K. 1986 46  used rapid kits with 
the  principle  of  Immuno  chromatography  which  were  commercially 
available.  Most  of  these  kits  simultaneously  detected  IgM  &  IgG 
antibodies  to  dengue  virus  in  human  whole  blood,  serum  or  plasma 
within 5-30 min.
N. Sathesh et al, CMC Vellore (2000)  62 had used rapid test by 
Pan  -   Bio  Rapid  Immuno  Chromatographic  card.  Out  of  154  serum 
samples  tested,  35(22.71%)  were  positive.  It  was  found  that  Immuno 
Chromatographic  card  test  was  100%  sensitive  and  was  able  to 
distinguish between primary and secondary infection.  
Branch  S.L  et  al  1999  5,  studied  the  serum  samples  from 62 
patients with the same kit and found the sensitivity to be 83.98%.
Attempts to create conventional vaccines have been hampered by 
the lack of suitable experimental models, the need to provide protection 
against all four serotypes, simultaneously and the possible involvement of 
virus-specific immune response in DHF / DSS (Stephensan J R 2006 69).
The first candidate dengue vaccines were developed shortly after 
the virus was discovered (Gubler D.J. 1998 28)
Both the WHO based initiative for  vaccines research (IVR) and 
paediatric  dengue  vaccine  initiative  (PDVI),  are  working  to  facilitate 
vaccine development.  Chimeric vaccines have been generated, the most 
advanced being, chimeric vax dengue.  In this vaccine, 17D yellow fever 
virion  and  envelope  protein  genes  are  replaced  with  those  from  the 
dengue viruses.  Other chimeric vaccines with cell adapted DEN2 viruses 
or dengue viruses with engineered mutation as genetic back bone have 
also been developed.  (Halstead S B and Dean 2002  35,  Stephenson. 
J.R. 2005 69 and Chaturvedi U.C. 2005 11)
Laboratory attenuated strains of each of the four dengue serotypes 
previously tested as monovalent  vaccines in volunteers were combined 
and tested for  immunogenicity,  safety and reactogenicity in 16 dosage 
combination.  Seven formulation met the serological criteria required for 
an expanded trail and three of these were sufficiently attenuated clinically 
to justify further testing (Guzman M J, Kouri 1990) 31. 
The only way to prevent dengue virus acquisition is to avoid being 
bitten  by  a  vector  mosquito,  wear  protective  clothing,  preferably 
impregnated  with  permerthin  insecticide  and  use  of  N1N1 
diethyl-3-Methyl benzamide (DEET) containing mosquito repellents. The 
use  of  mosquito  netting  is  of  limited  benefit  as  aedes  are  day  biting 
mosquitoes.   Elimination  of  the  mosquito  vector  using  indoor  sprays, 
elimination of  breeding grounds of the mosquitoes by not allowing them, 
access to small accumulations of stagnant water around human habitats 
such as found in pots, old tubes, on any vessel capable of holding water, 
and  to  support  community  based  vector  control  programme  are  other 
options  available  as  control  measures.  (Dengue  Hemorrhage  Fever., 
WHO, 1997 76)
MATERIALS AND METHODS
This study was conducted at Government Rajaji Hospital, attached 
to  Madurai  Medical  College,  Madurai  and  Centre  for  Research  in 
Medical Entomology, Madurai.  The study period was for 8 months from 
November  2005 to  June  2006 and  the  study  population  included  125 
suspected  cases  of  Dengue  fever  with  5  –  10 days  duration.   Ethical 
clearance was obtained from Hospital ethical committee chairman.
The inclusion criteria for the study population were 
1. Acute febrile illness of 5-10 days duration with 2 or more of the 
following symptoms.
a. Head ache
b. Retro orbital pain
c. Myalgia
d. Arthralgia
e. Rash
f. Haemorrhagic Manifestation
g. Leucopenia
2. Age group ranging from 6 months to 65 years 
The exclusion criteria were
a. Febrile cases without the above symptoms
b. Children below 6 months and above 65 years (extremes 
of ages)
c. Haemorrhagic  conditions  without  evidence  of  Dengue 
fever.
Collection and Transportation of samples:
The blood samples were collected from the patients admitted in 
Government Rajaji Hospital from both endemic and non endemic areas 
for dengue viruses.  Aseptically, 2-5 ml of blood was collected in vials 
with screw caps.   The caps  were fixed with adhesive  tape to  prevent 
leakage  during  transport.   The  specimens  were  transported  to  the  lab 
immediately in an ice box with proper labeling of the name of the patient, 
identification number and date of collection.
Processing of Samples
As soon as the samples were received in the laboratory, they were 
centrifuged and serum was separated.  The serum samples were stored in 
the refrigerator at 4OC and tested within a week, if  there is a delay it 
should be stored at -20 OC. 
The collected specimen were processed for 
Methodology I
Detection  of  dengue  IgM  /  IgG  antibodies  by  BIAS-3  dengue 
IgG/IgM kit. 
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IgM capture ELISA 
Methodology III
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the IgM positive sera intra cerebrally in suckling mice and harvesting the 
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Methodology IV
Confirmation  of  the  dengue  antigen  titre  by  Haemagglutination 
technique. 
Methodology V
The  harvested  brain  materials  were  subjected  to  RT -  PCR for 
amplification of 511 bp  C-PreM gene region of dengue virus. 
Methodology VI
Single tube multiplex PCR analysis employing dengue sero type 
specific amplimers.
I. Detection of Dengue IgG / IgM antibodies by BIAS - 3
This is a two step assay for the differential detection of IgG and 
IgM  antibodies  to  Dengue  virus  in  serum.   The  test  kit  is  a  rapid 
membrane based screening test  to differentially  detect  the presence of 
antibodies to dengue virus.  This test is the newer generation lateral flow 
immunochromatographic type assay.  
Principle
The  test  employs  the  use  of  two  antibody  binding  proteins 
conjugated  to  colloidal  gold  particles  and  a  unique  combination  of 
Dengue  antigens  immobilized  on the  membrane.   Once  the  sample  is 
added to the sample pad along with the diluent, the mixture passes bi-
directionally through the antibody binding / gold complexes, which then 
binds the immunoglobulins in the sample.  As these complex passes over 
the immobilized antigen on the membrane,  if  any antibody to Dengue 
(IgG/IgM) are present the antigen capture them in turn.  This produces a 
pink / purple band in the Test zone of the device.  The remaining complex 
continues to migrate to a control area on the test device and produces a 
pink / purple band in each Control area.  This control bands indicate that 
the test has been performed properly.
Test Procedure:
The  kits  were  removed  from  the  pouches  and  kept  in  a  clean 
surface. 5 µl of the serum sample was added to the centre hole indicated 
by an ‘S’  on the  device.  6  drops of  sample  diluent  was  added to the 
central hole.  Development of purple band was taken as positive result.  
Dengue IgM capture ELISA
The  qualitative  immuno  enzymatic  determination  of  IgM  class 
antibody  against  dengue  virus  is  based  on  ELISA  (Enzyme  Linked 
Immuno Sorbent Assay) 
Technique
Micro titre strip wells are pre coated with dengue virus antigen to 
bind the corresponding antibodies of the specimen.  After washing the 
wells to remove all unbound sample material, add antigen – Mab tracer 
solution  is  added.  This  conjugate  binds  to  the  captured  dengue  virus 
specific antibodies.
The immune complex formed by the bound conjugate is visualized 
by adding tera methyl  benzidine (TMB),  substrate  which gives a blue 
reaction  product.   The  intensity  of  this  product  is  proportional  to  the 
amount  of  dengue  virus  specific  IgM  antibodies  in  the  specimen. 
Sulphuric acid is added to stop the reaction.  This produces a yellow end 
point.  Color absorbance at 450 nm is red using an ELISA micro well 
plate reader.  
Procedure:
1. Sample  dilution:   As  per  kit  instructions  all  samples  were 
diluted 1:100 with IgM sample diluent.   10µl of sample was 
diluted  with  1ml  of  IgM.  Samples  were  diluted  in  tubes  to 
obtain  a  1:100  dilution  and  thoroughly  mixed  in  the  vortex 
mixer.  
2. Dilute  the  antigen  provided,  with  antigen  diluent.   10μl  of 
antigen is added to 2.5ml of antigen diluent.
3. Remove the required volume of diluted antigen and mix with an 
equal volume of Mab tracer in a clean glass or plastic vial.  Mix 
gently and leave at room temperature (20-25OC) until use.
Methodology:
One well was allotted for the substrate blank, two well for negative 
control and one well for positive control.
The specimens as well as the positive and negative controls were 
added in to their respective wells.  One well was left for substrate blank.  
The wells were covered with the foil supplied in the kit.  This was 
incubated for 1 hour at 37OC.  After this step,  the foil was removed, the 
contents aspirated from the well and washed 6 times with wash buffer. 
The remaining fluid in the well was removed by tapping on tissue paper.
100µl of dengue virus antigen Mab tracer solution was added into 
all the wells except for the blank well and covered with foil.  This was 
incubated   for  1  hour  at  37OC. At  the end of  1  hour,  the  wells  were 
washed  6  times  with  diluted  wash  buffer.   100µl  of  TMB  substrate 
solution was added to all the wells and this was incubated for 10 minutes 
at room temperature in the dark and blue colour developed.  100µl of stop 
solution was added to all the wells, the blue color developed during the 
incubation  turned  into  yellow.    The  absorbance  of  the  specimen  at 
450 nm within 30 minutes after the addition of stop solution was read in 
ELISA reader.  The absorbance value of all the wells at 450 nm were 
recorded for each specimen.
Calculations:
The average absorbance of the triplicate of the cut of calibrator was 
calculated, which was the cut off value.
Interpretation of Results:
A positive  results  (≥  11 PANBIO Units)  is  indicative  of  either 
primary or secondary infection.
III. Isolation of Dengue Virus:
Specimen – Serum
Animals used were Swiss Mice (1 – 2 days) Sucking Mice 
Animal Inoculation:
Virus Isolation:
Attempts were made to isolate the virus by inoculating the serum 
sample  in  0  to  2  days  old  suckling  mice  (swiss  mice),  using  1ml 
tuberculin syringe with 25gauge needle. About 0.01ml – 0.02ml of serum 
was inoculated slightly lateral to the midline and into the mid portion of 
the lateral hemisphere.  Each sample was inoculated in 6 – 8 mice in a 
litter.  
After inoculation, the mice were observed daily for the sickness. 
Mice that die in fewer than 24 hours were discarded.  After 24 hours,  the 
mice were observed twice a day for any signs of abnormal behaviour. 
Signs  were  absence  of  milk  in  stomach,  dark  color,  wasting,  unusual 
activity, tremors, seizures or prostration.
Mice that developed sickness were euthanized, and the brain was 
harvested  by  removing  the  skull  cap  aseptically  with  scissors.  The 
harvested  mice  brains  were  stored  in  sterile  borate  saline  and kept  at 
minus 70OC until use. 
IV.  Haemagglutination  Test  (for  confirmation  of  Dengue  Antigen 
Titre)
A wide variety of  animal  viruses  has been shown to posses  the 
capacity of adsorbing to red cells and in many cases causing agglutination 
of  these  red  cells.  This  haemagglutination  test  furnished  a  relatively 
simple,  quick,  convenient  and  fairly  quantitative  way  of  detecting, 
identifying and titrating viruses.
Procedure:
Mark the micro  titre  plate with the glass  marking pencil  giving 
different dilution of antigens.
With a 0.05ml dropper add one drop of 0.4% BABS to each well.
Keep plate in refrigerator for chilling.
Keep seven 0.05ml micro diluters with tips immersed in 0.9% 
          NaCl in refrigerator for chilling.
Dispense 0.9 ml of 0.4% BABS in a tube in an ice bath.
Add 0.1ml of antigen and mix thoroughly (1:10 dil. of antigen)
Remove plate and microdiluter from the refrigerator.
Blot 0.05ml micro diluters on blotting paper, dip the tips in tube 
with 1:10 antigen and place in each of wells marked 1:20 in the 
plate.
With the microdiluters, prepare serial two fold dilutions of antigen 
through  well  10  by  swirling  the  microdiluters  10-15  times 
(1:10240).
Add 2.4 ml of Virus Adjusting Diluent (VAD) 6.0, 6.2, 6.4, 6.6, 
6.8, 7.0, 7.2 to labeled tubes.
Add 0.1 ml of 10% RBC to each tube and mix well (This gives a 
dilution of 0.4% RBC)
With  a  0.05  ml  dropper  pipette  add  one  drop  of  RBC  to 
corresponding row. 
Tap plate or use shaker to mix cells and antigen dilutions.
Cover the plate and incubate at room temperature until cells in the 
wells  to cell  controls  settle  and form a button (usually  about ½ 
hour)
Read and record the titration.
Complete  agglutination  consists  of  a  layer  of  uniformly 
agglutinated  cells  covering  the  entire  lower  surface  of  the  well.   A 
negative  pattern  consists  of  a  compact,  sharply  demarcated  button  of 
sedimented cells in the centre of the well, the pattern being in identical to 
that seen in the control wells.
V. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Equipments Needed
 Programmable thermal cycler
 Electrophoresis unit
 Power pack
 Agarose gel electrophoresis tank, tray and combs
 UV transilluminator
 Dark room photographic equipment
 Gel doc
 UV face shields
 Set of micropipettes
 Sterile microfuge tubes (1.5ml and 0.5ml)
 Sterile tubes for thermal cycler
 Sterile micro pipette tips
 Ice bucket
Reagents Required
 Template RNA
 Oligonucleotide primer  
∗ R T primer, Forward primer, Reverse primer
 RT buffer
 Taq polymerase
 Magnesium chloride
 d NTP mix
 Agarose
 IXTAE buffer
IDENTIFICATION OF VIRUS BY RT-PCR
RNA Extraction for RT-PCR
The total RNA of virus infected mouse brain was extracted using 
TRIZOL reagent as per the manufacturer’s instructions.
Homogenization:
750  µl of Trizol reagent was added to 250µl of brain suspension 
(50-100 mg tissue) and the homogenate was incubated for 10 minutes at 
room temperature.  Two hundred microlitre of cholorform was added and 
mixed vigorously.  The samples were incubated for 2-3 minutes at room 
temperature and centrifuged at 10,000 rpm (12,000g) for 15 minutes at 
4OC in a refrigerated centrifuge.
RNA Precipitation:
The colourless upperface was collected and transferred to another 
sterile  microcentrifuge  tube.  0.5ml  of  isopropanol  was  added  and 
incubated  for  5-10  minutes  at  room  temperature.   Samples  were 
centrifuged at 10,000 rpm for 10 minutes at 4OC. 
RNA wash:
The supernatent was removed and the pellet was suspended in  1ml 
of 75% Ethanol and centrifuged at 5000 rpm for 5-10 minutes at 4OC.  
Solubilization:
The RNA pellet was air dried for 5-10 minutes and dissolved in 20-
30  µl  of  sterile  milliQwater.  The  samples  were  incubated  at 
60 OC to  65 OC for 10 minutes. 
Virus Identification using RT-PCR:
Reverse  transcriptase  PCR (RT-PCT)  has  been  developed  for  a 
number  of  RNA  viruses  in  recent  years  and  has  the  potential  to 
revolutionize laboratory diagnosis.  RT-PCR provides a rapid serotype-
specific  diagnosis.   The  method  is  rapid,  sensitive,  simple,  and 
reproducible if properly controlled and could be used to detect viral RNA 
in human clinical samples, autopsy tissues, or mosquito samples.
Protocol:
RT – PCR was carried out as per Lanciotti et al 1992, virus capsid 
region was amplified by using specific primers.
The virus specific primers were synthesized commercially and the 
sequences were obtained from the published reports.
1.  43µl  of  Rnase  free  H2O  and  1µl  of  reverse  primer  (DCP-B  gene 
specific) and 1µl of gene specific forward primer (DCP-A) was added to 
the beads i.e.  commercially  available  RT PCR kit.   The primers were 
developed commercially (Q1AGEN).
2. To the tubes,  5µl of RNA Template of each sample was added.
3.  All  the  PCR  tubes  were  kept  in  Thermocycler  (Master  cycler, 
eppendoff) and the RT-PCR was carried out by the following temperature 
cycle. 
PCR Program
1. Step1 42 OC  1hr                         cDNA synthesis   
35cycles of
2. Step 2 94 OC – 1min Denature
3. Step 3 55 OC – 1 min Anneal
4. Step 4 72 OC – 1 min Extension
5. Step 5 72OC – 10 min Final extension
DETECTION AND DOCUMENTATION OF RESULTS:
After the PCR is over, the products were visualized in Agarose gel 
electrophoresis stained with Ethidium bromide.
1.2% Agarose  gel  was  prepared  in  0.5  x  TBE buffer,  to  this  2µl  of 
Ethidium bromide was added and allowed to polymerize.
After  polymerization,  the gel was immersed in the gel tank with TBE 
buffer. 6 µl of 100bp DNA Ladder (GENEI) was used.  10µl of the PCR 
product (samples) was mixed with 2µl of loading dye.
The gel was electrophoresised at 70-80v (5v/sq.cm) till the dye reached 
the half of the gel tray.
The gel was removed and was placed on UV transilluminator.
Methodology VI
Single  tube multiplex  PCR analyis  employing dengue sero  type 
specific amplimers.
Rapid  assay  by  which  a  second  PCR,  with  specific  primers 
allowing  sero  type  identification  (DNA  Products)  of  different  sizes 
according to the dengue sero type obtained.
RESULTS
A total of 125 suspected Dengue cases admitted in the pediatric 
and  Medical  Wards  of  Government  Rajaji  Hospital  during  November 
2005 – June 2006 were analysed for the distribution of cases month wise 
and it was found that there were 10 cases in November (8%), 15 cases in 
December  (12%),  23  cases  in  January  (18.4%),  16  cases  in  February 
(12.8%), 22 cases in March (17.6%), 30 cases in April (24%), 5 cases in 
May (4%) and 4 cases in June (3.2%).  Thus the distribution of cases 
from January – April found more than the other months.  This is given in 
Table No 1.
TABLE 1
MONTH WISE PREVALENCE OF DENGUE
Sl. No. Month Number
1 November 10 (8%)
2 December 15 (12%)
3 January 23 (18.4%)
4 February 16 (12.8%)
5 March 22 (17.6%)
6 April 30 (24%)
7 May 5 (4%)
8 June 4 (3.21%)
The samples  were analysed according to  the place of  collection 
especially from endemic and non endemic areas for dengue, and it was 
found that 30 samples (24%) were collected from endemic areas and 95 
samples (76%) were collected from non endemic areas.  This is given in 
Table 2.  
TABLE 2
PREVALENCE OF DENGUE
Sl.
No.
Dengue Endemic 
areas
Total 
samples 
collected
% of 
samples 
collected
Dengue Non – 
Endemic areas 
Total 
samples 
collected
% of 
samples 
collected
1 Chatrapatty 8 26.6% Valanthur 26 27.36%
2 Pilliarpatty 12 40% Senthurai 34 35.78%
3 Virudhunagar 6 20% Poosaripatty 18 18.94%
4 Kalaiyarkoil 4 13.3% Chettikulam 17 17.89%
TOTAL 30 24% 95 76%
Among the 125 cases studied 72 were males (57.6%) and 53 were 
females (42.4%), thus it  was found that the incidence was high in the 
males.  The samples were further analysed agewise and sexwise and it 
was found that among the 72 males, 38 cases were in the 0-15 years age 
group (30.4%), 14 were in the 16-30 years group (11.2%), 12 were in the 
31-45 years group (9.6%), 5 were in 46-60 years group (4%) and 3 were 
in more than 60 years age group (2.4%).  Similarly among 53 females, 24 
were in the age group 0-15 (19.2%), 13 were in the age group of 16-
30(10.4%), 9 were in the age group of 31-45(7.2%), 5 were in the age 
group of 46-60 (4%) years and 2 were in the age group above 60 years 
(1.6%). It was found that the age group commonly involved in both sexes 
were between 0-15 years.  This is given in Table 3.  
TABLE 3
                AGE WISE AND SEX WISE PREVALENCE OF 
DENGUE 
Sl. No. Age Group Male Female Total
1 0-15 38 (30.4%) 24 (19.2%) 62 (49.6%)
2 16-30 14 (11.2%) 13 (10.4%) 27 (21.6%)
3 31-45 12 (9.6%) 9 (7.2%) 21 (16.8%)
4 46 – 60 5 (4%) 5 (4%) 10 (8%)
5 > 60 3 (2.4%) 2 (1.6%) 5 (4%)
Total 72 (57.6%) 53 (42.4%) 125 (100%)
All the 125 samples were further analysed according to the clinical 
manifestation and it was found that 117 cases had Dengue Fever (93.6%), 
8 had Dengue Haemorrhagic Fever (6.4%), and there were no case with 
Dengue Shock Syndrome.  Thus more cases were found with clinical 
manifestation of dengue fever.  This is given in Table 4.
TABLE 4
                CLINICAL MANIFESTATION WISE ANALYSIS OF 
DENGUE CASES
Sl. No. CLINICAL 
MANIFESTATION
TOTAL NUMBER
1 DENGUE FEVER 117 (93.6%)
2 DENGUE 
HAEMORRHAGIC FEVER
8 (6.4%)
3 DENGUE SHOCK 
SYNDROME
-
TOTAL 125 (100%)
The samples were further analysed according to the symptoms 
and it was found that fever was present in almost all cases.  Fever 
with  headache  in  101 (81.5%) cases,  Fever  with  myalgia  in  106 
(84.5%),  Fever  with  rash  in  15  (12%)  cases  and  Fever  with 
Haemorrhagic manifestation in 8 (6%) cases.  Thus it was found 
that fever with myalgia was the commonest symptom found in 
the cases.  This is given in Table 5. 
TABLE 5
SYMPTOM WISE ANALYSIS OF DENGUE CASES
Sl. No. SYMPTOMS TOTAL 
1 Fever with headache 101 (81%)
2 Fever with myalgia 106 (84.5%)
3 Fever with arthalgia 40 (32%)
4 Fever with Haemmorhagic 
manifestation
8 (6%)
The samples were further analysed according to the Clinical Signs 
and  it  was  found  that  9  (7%)  had  Splenomegaly,  10  (8%)  had 
Hepatomegalyy,  25  (20%)  had  rash  and  4  (3.7%)  had  a  positive 
Tourniquet test, and 61.4% cases showed no signs.   Thus rash was seen 
as the commonest clinical sign.    This is given in Table No. 6
TABLE 6
SIGNS ELICITED
Sl. No. SIGNS TOTAL 
1 Splenomegaly 9 (7%)
2 Hepatomegaly 10 (8%)
3 Rash 25 (20%)
4 Tourniquet test 4 (3.6%)
5 No Signs 77 (61.4%)
The analysis of samples for the presence of IgM/IgG antibodies by 
BIAS-3 Dengue IgG/IgM Immuno Assay System showed that out of 125 
samples 15 (12%) were positive for IgM antibodies and 4 (3.2%) were 
positive for IgG antibodies. This is given in Table No. 7. 
TABLE 7
DETECTION OF IgM / IgG Antibodies by BIAS-3 Kit
ANTIBODIES POSITIVE 
IgM 15 (12%)
IgG 4 (3.2%)
Further  analysis  of  the  15  IgM  positive  cases  showed  that  14 
belonged to the dengue fever category and 1 patient belonged to Dengue 
haemorrhagic fever category, and the 4 IgG positive cases showed that all 
of  them  belonged  to  the  Dengue  fever  group.   This  is  shown  in 
Table No. 8. 
TABLE 8
CLINICAL STATE WISE ANALYSIS OF IgM / IgG ANTIBODIES BY 
BIAS-3 KIT
Sl.No. CLINICAL 
STATE
IgM IgG TOTAL
1 DF 14 (11.2%) 4 (3.2%) 18 (14.4%)
2 DHF 1 (0.8%) 0 1 (0.8%)
3 DSS - - -
TOTAL 15 (12%) 4 (3.2%) 19 (15.2%)
Sex wise and age wise analysis of IgM and IgG antibodies was 
done.  Among the 15 IgM positive cases, 9 cases (60%) were males and 6 
cases (40%) were females.   Age wise analysis of the 15 IgM positive 
cases, showed that 10 cases were in the 0 – 15 years age group (66.6%) of 
which,  7  cases  were males  (46.6%) and 3 cases  were females  (20%). 
Thus IgM antibodies were more commonly found in males in the age 
group 0 – 15 years. This is given in Table No. 9.
TABLE 9
                AGE WISE AND SEX WISE ANALYSIS OF IgM 
POSITIVE 
Sl. No. Age Group Male Female TOTAL
1 0 – 15 years 7 (46.6%) 3 (20%) 10 (66.6%)
2 16 – 30 years 2 (13.3%) 1 (6.66%) 3 (20%)
3 31 – 45 years - 1 (6.66%) 1 (6.66%)
4 46 – 60 years - 1 (6.66%) 1 (6.66%)
5 > 60 years - -
TOTAL 9 (60%) 6 (40%) 15 (100%)
Similarly the IgG positive samples were analysed age wise and sex 
wise and it  was found that  among the 4 positive cases,  2 were males 
(50%) and 2 were females (50%).  Among these 4 cases, 2 cases were 
found in the 16 – 30 years group (50%), 1 was male (25%) and 1 was 
female (25%).  Similarly the remaining, 2 (50%) cases were found in the 
31 – 45 years age group among these 1 was male (25%) and 1 was female 
(25%). Thus IgG antibodies were found equally in males and females 
in the age group of 16 – 45 years.  This is given in table 10.  
                                             TABLE 10 
AGE WISE AND SEX WISE ANALYSIS OF IgG POSITIVE 
Sl. No. Age Group Male Female TOTAL
1 0 – 15 years - - -
2 16 – 30 years 1 (25%) 1 (25%) 2 (50%)
3 31 – 45 years 1 (25%)    1 (25%)   2 (50%)
4 46 – 60 years - - -
5 > 60 years - - -
TOTAL 2 (50%) 2 (50%) 4 (100%)
The 19 positive samples by BIAS – 3 system were further analysed 
for the confirmation of IgM positivity by Pan Bio Dengue IgM capture 
ELISA and it was found that all the 15 IgM positive by BIAS – 3 dengue 
IgG / IgM Immuno assay were positive by Pan Bio IgM capture ELISA, 
and the 4 IgG positive were negative by PAN BIO IgM capture ELISA. 
This is given in Table 11.
TABLE 11
RESULTS OF IgM BIAS – 3 KIT AND PAN BIO IgM CAPTURE 
ELISA
Sl. No. Kit used
Total No. 
of Tested
Number of Positive
IgM IgG Total
1 BIAS – 3 Dengue IgG / 
IgM Immunoassay
125 15 (12%) 4 (3.2%) 19 (15.2%)
2 Pan Bio IgM Dengue 
Capture ELISA
19 15 (78.9%) - 15 (78.9%)
 
The 15 IgM positive sera samples were injected intra cerebrally 
into suckling mice and it was found that 10 out of 15 positive samples 
produced hunch back,  less  intake of  food and fine  tremors  leading to 
paralysis within 4 – 5 days of post inoculation.  2 samples produced only 
weakness but no paralysis or convulsions and 3 samples produced only 
prostration but no paralysis.  This is given Table No. 12
TABLE 12
                RESULTS OF VIRUS ISOLATION
SL. 
NO. TOTAL
TYPICAL (SICK 
+ PARALYSIS + 
CONVULSIONS)
WEAKNESS + 
NO PARALYSIS 
+ NO 
CONVULSIONS 
ONLY 
PROSTRATION 
NO 
CONVULSIONS
1 15 10 (66.6%) 2 (13.3%) 3 (20%)
  
The HA titre of the brain tissue was determined in the 10 samples 
which showed positive symptoms and the titres were found as follows.
TABLE 13
HAEM AGGULITINATION TITRES
Sample 
No.
Titres
10 10-40 40-80 80-160 160-320 > 320
1 - - - Present - -
2 - - - - Present -
3 - - - Present - -
4 - - - Present - -
5 - - - Present - -
6 - - - - - Present
7 - - - Present - -
8 - - - - Present -
9 - - - - - Present
10 - - - Present - -
TOTAL 0 0 0 6 (60%) 2 (20%) 2 (20%)
 
Among the 10 samples, 6 showed titres between 80 – 160 (60%), 
2 showed titres between 160 – 320 (20%) and 2 showed titres more than 
320 (20%).  Thus 4 samples showed titres ranging from 160 – 320.  All 
the 10 samples were further processed by RT PCR to find the base pair 
region of  the  Dengue  virus.   It  was  found  that  out  of  10  samples,  4 
samples  which  showed titres  more  than  160,  showed  amplification  at 
511 bp C-Pre M region denoting that  it  is  a dengue complex.   These 
dengue complex positive samples were analysed age wise, sex wise and 
according to clinical state and it was found that all the four samples were 
from males in the age group ranging from 3 – 9 years, 3 of them showed 
fever  and one  showed haemorrhagic  manifestations.   This  is  given  in 
Table No. 14. 
TABLE 14
CLINICAL STATE AND PCR ANALYSIS
SL. 
NO.
CLINICAL 
STATE AGE/ SEX
RT-PCR 
511 bp % POSITIVE
1 DF 37 / F Negative
40%
2 DF 7 / M Positive
3 DF 5 / F Negative
4 DF 45 / F Negative
5 DF 16 / M Negative
6 DHF 9 / M Positive
7 DF 41 / M Negative
8 DF 8 / M Positive
9 DF 3 / M Positive
10 DF 30 / F Negative
These Dengue complex positive samples were further analysed by 
using single tube multiplex PCR to find out the serotype of the complex 
using Dengue serotype specific amplimers. All the four samples analysed 
showed the presence of Dengue 3 specific 290 bp amplicon denoting the 
serotype belonged to Type 3. This is given in Table No. 15. 
                TABLE 15
                    SERO TYPE ANALYSIS
SL. 
NO.
CLINICAL 
STATE
AGE/ 
SEX
RT-PCR 
511 bp
SERO TYPE
(290 bp amplicon)
1 DF 7 / M Positive TYPE III
2 DF 8 / M Positive TYPE III
3 DHF 9 / M Positive TYPE III
4 DF 3 / M Positive TYPE III
DISCUSSION
The study of  Prevalence of  dengue sero type in Madurai by 
molecular  methods involved 125 suspected  dengue cases  admitted  in 
Government Rajaji Hospital during November 2005 – June 2006.
In  the  present  study,  it  was  found  that  57.6%  of  the  affected 
population were males and 42.4% were females.  Gadia R R et al  21 in 
his  study had shown that  70% of the affected  population were males. 
Similar  studies  of  Gupta  et  al  30 also  demonstrated  the  incidence  of 
dengue  infection  were  more  in  males,  the  ratio  being  2.1:1.  These 
findings support the present study, whereas the study by Rita Maria et al 
59 showed that the incidence was more in females than males, the ratio 
being  1:1.08.  The  study  by  Philip  Samuel  et  al  55 revealed  no  sex 
difference in these cases.  Susan Shepherd et al 71 says that the dengue 
infection occur irrespective of sex.  But in the present study there were 
more number of males than females, this might be due to the selection of 
more number of cases from villages, where the dressing culture of the 
males  favoured  the  biting  by  the  mosquitoes  while  compared  to  the 
females.
In the present study agewise analysis of the samples revealed that 
the commonest age group affected was  0 – 15 years in both males and 
females.  Similar study by Victor J et al and Soundaravally et al 73, 67 
also revealed the occurrence of dengue infection commonly in the age 
group 0 – 15 years, the percentage being 65% and 34.2% respectively. 
This  might  be  due  to  the  endemicity  of  the  infection  in  many  of  our 
population, where the older and many younger inhabitants are immune, 
where as the children between 0 – 15 years are more affected.
In  the  present  study  it  was  found  that  the  number  of  samples 
collected from January to April were more, with the maximum number 
of cases in April 2006 (24%).  This period is neither a pre monsoon nor 
a post  monsoon.   Thakara et al  72  in his study stated that  increased 
number of cases in dengue infection were mainly related to the cyclic 
changes  in  weather  which  favoured  the  breeding  of  A.  aegypti. 
G S Chouhan et al  13   of Rajasthan also demonstrated more number of 
sample collection during the pre monsoon period.  A study by  Emran 
Pin Yunus et al  20  of Bangladesh,  Mahbubur Rahman et al  50 also 
revealed the incidence was more common in the post monsoon season for 
obvious reasons.   Even though these studies do not correlate with my 
studies,  it  was found that  we had two unusual  rains during December 
2005  and  March  2006,  perhaps  these  might  be  the  reason  for  the 
increased number  of  cases  in January and April,  which were the post 
raining months, in which the breeding of A. aegypti mosquitoes would 
have been encouraged.  
In  the  present  study  it  was  found  that  dengue  fever with  out 
clinical manifestation of haemorrhage were common (93.6%) followed 
by dengue haemorrhagic fever (6.4%) and there was no case of dengue 
shock  syndrome.  The  study  by  Manoj  Kumar  et  al  51, New  Delhi 
showed an incidence of dengue fever in 75% cases, dengue haemorrhagic 
fever in 21.9% cases and dengue shock syndrome in 3.1% of cases.  The 
study by  Mahbubur Rahman et al  50 also revealed 60% dengue fever 
followed by 39.2% dengue haemorrhagic fever and 0.6% dengue shock 
syndrome.  All these studies favour our findings except that there was no 
dengue shock syndrome reported in my study.  As most of my cases were 
from the non endemic areas of dengue infection, the antibody dependent 
enhancement and replication of dengue virus in cells of mono nuclear cell 
lineage  would  not  have  occurred,  hence  no  secretion  of  vasoactive 
mediators, resulting in shock. 
The clinical symptom of dengue commonly involved in my study 
was fever with myalgia 84.5%, whereas fever with headache accounted 
for  81% and  fever  with  arthralgia  accounted  for  32% and  fever  with 
haemorrhagic manifestation accounted for 6%.  The study by Gadia R R 
et  al  21 also  revealed  that  most  of  the  cases  in  their  study  showed 
symptoms of fever with headache 87%, fever with myalgia 70%, fever 
with arthralgia 54.9%.  This is in support of my findings denoting fever 
with myalgia, is the most common symptom in dengue cases.
In the present  study,  the commonest  sign elicited in the dengue 
cases were rash 20% followed by  splenomegaly in 7%, hepatomegaly in 
8%, positive tourniquet test in 3.2%. Similarly the study by Kabilan L et 
al 44  demonstrated  that  55.2% of  his  cases  had rashes.   The study by 
Gadia R R et al  21 also revealed the presence of rash in 21% of cases, 
splenomegaly  in  11%  and  hepatomegaly  in  17%  and  the  positive 
tourniquet test in 11%.  All these studies are in support of our findings, 
denoting  the  commonest  signs  elicited  in  dengue  infection  was  the 
rash.
In the present study IgM antibodies were demonstrated in 15 (12%) 
and IgG was demonstrated in 4 (3.2%).  14 out of the 15 IgM positives 
belonged to the dengue fever category (11.2%) and 1 belonged to the 
dengue haemorrhagic fever category (0.8%) and all the IgG positive cases 
belonged to the dengue fever group 3.2%.  Thakara J P et al  72 in his 
studies demonstrated that 14.6% cases were positive for IgM antibodies. 
Similarly, study by Philip Samuel et al  55 also revealed 14.4% positive 
for IgM antibodies.   All these IgM positivity were detected in dengue 
fever cases.   The study by  Sathish et al  62, CMC also showed 22.7% 
positivity.  All these studies are in support of our study, revealing that 
IgM antibody is found more commonly in dengue fever cases.  In the 
present study it was found that IgM antibodies were commonly found in 
males in the age group 0-15 years (46.6%), whereas the IgG antibody was 
found equally in males and females in the age group of 16 – 35 years.
The appearance of IgG antibodies in the older age group may be 
due to the secondary immune response elicited by these cases,  due to 
prior infection, where as the younger age group, in whom the primary 
immune  response  is  common,  IgM  antibodies  were  elicited.  This  is 
explained by Ravulapalli Anandha Rao et al 58.
In the present study IgM capture ELISA has proved to be the best 
confirmatory test by eliciting 78% positivity in the IgM positive cases 
screened  by  BIAS 3  kit.   Similarly  study  by  Soundaravally  et  al  67 
showed 85.2% positivity by Mac ELISA.  But Rita Maria et al 59 showed 
IgM positive by Mac ELISA to be 53.3% and study by De Paulo et al 16 
showed a positivity of 27.9%.  The variation in the positive rate is due to 
the usage of IgM capture ELISA either as a screening or confirmatory 
methodology.  In our study we used it as a confirmatory methodology, 
whereas the other studies used it as a screening methodology.  
In the present study it was shown, that virus was isolated in 10 out 
of  15  IgM positive  samples  by Intracerebral  inoculation  into  suckling 
mice (66.6%).  Similar studies by Parida M M et al 54 demonstrated 80% 
virus  isolation  in  suckling  mice.   This  is  in  support  of  our  finding, 
whereas Ratho R K et al 57, Chandigarh showed the isolation rate from 
suckling mice was 23.8%.  This variation in isolation rate might be due to 
the selection of animals showing positive symptoms.  In my study I have 
selected only the sick animals with paralysis and convulsion.  Although 
some animals showed weakness and prostration as they did not produce 
paralysis or convulsions, these animals were not considered.
            In the present study, haemagglutination (HA) was used as the 
confirmatory test  for the identification of the dengue virus in suckling 
mice brain and HA titres ranging from 80 to 320 were taken as positive. 
All the brain tissues inoculated with IgM positive samples showed these 
titres. The confirmatory test for the dengue antigen detection varied in 
various  studies.   Ratho  R  K  et  al  57 has  used  indirect  immuno 
fluorescence  test  as  a  confirmatory  test.   Philip Samuel  et  al  55 used 
mosquito inoculation technique followed by direct immuno fluorescence 
to be the confirmatory test for dengue antigen.  
In the present study, out of the 10 IgM positive samples subjected 
to RT-PCR, only 4 yielded amplification of 511bp C-Pre M region of 
dengue virus (40%).  Out of the 4 RT-PCR positive samples, 3 of them 
presented with dengue fever and 1 showed haemorrhagic manifestation. 
Similar study by Manoj Kumar et al 51 revealed 21.8% positive by RT-
PCR and study by Rita Mario et al 59 revealed 32% positive by RT-PCR 
and the study by  Ratho R R et al  57 revealed 78.9% positivity by RT-
PCR.  As our samples were collected during 5 – 10 days of onset  of 
symptoms, detectable level of dengue specific IgM antibodies, appearing 
after 4 – 5 days was demonstrated in most of our samples, whereas the 
molecular test showed less number of positivity because the ideal time for 
collection  of  samples  for  PCR  testing  was  between  1  –  5  days  as 
described by Manoj Kumar et al 51.  
In the present study it was found that there was an emergence of a 
different  sub  type  of  dengue  virus  at  Madurai.   In  the  present  study 
dengue – 3 was seen as the predominant type whereas in our previous 
studies we have demonstrated dengue type 2 as the predominant  type. 
Manoj Kumar et al 51 had already explained the replacement of one type 
of dengue by the other by the fact that in 1971, dengue 2 was introduced 
in the Pacific followed by dengue 1 in 1975 and dengue 4 in 1979 and 
dengue 3 in 1980.  Dengue 3 had been already reported from various 
parts of India, South East Asian Countries and in the Americas.  The first 
reported evidence of dengue 3 in Delhi was in 1970, in Jamaica was in 
1963,  in  Columbia  was  in  1970,  in  Pacific  Island  was  in  1980  and 
Americas was in 1994.    
The  study  of  Dash  P  K  et  al  15, Defence  Research  and 
Development  Establishment,  Gwalior,  2003 showed the  implication  of 
Dengue  type  3,  in  an  out  break  of  dengue  infection  that  occurred  in 
northern India during October – December 2003.  The study by William 
B Messer et al 78 showed that the dengue type 3 was responsible for the 
out  breaks  in  Sri  Lanka  and  Bangladesh  (2003).   This  confirms  the 
reemergence  of  dengue  type  3  in  a  dominant  form  in  the  Indian 
subcontinent.  Soundravally R et al 67 also showed the presence of type 3 
in the dengue out break that occurred in October 2003 – February 2004. 
Sequencing of the amplicon from the isolated dengue type 3 confirmed 
the  sero  type and phylogenetic  analysis  based  on nucleotide  sequence 
showed  the  closeness  of  the  Pondicherry  strains  to  Peru  and  Taiwan 
strains.  
Ramamurty N et al 56 in their study carried out in Chennai showed 
the presence of both sero types 2 and 3.  Rita Maria Riberio Nouguiria 
et al 59 from Brazil has also reported dengue virus type 3 in the summer 
epidemic  of Rio de Janeiro.  All  these study reports  are similar  to our 
findings.         
SUMMARY
The study of  prevalence of  dengue sero type in Madurai  by 
molecular  methods was  aimed  at  finding  the  sero  type  of  dengue 
prevalent in Madurai during the period November 2005 – June 2006, by 
molecular  methodology.   Out  of  125  dengue  suspected  dengue  cases 
admitted  at  Government  Rajaji  Hospital,  Madurai,  it  was  found  that 
more number of cases were admitted from January – April 2006, which 
was  neither  a  pre  monsoon  nor  post  monsoon  period,  but  due  to  the 
unusual  rains  in  December  2005  and  March  2006,  leading  to  more 
number  of  cases  reported during this  period.   In  the  study population 
57.6% were males and 30.4% of these males were in the age group of  0 – 
15 years.  
The commonest symptom present in 84.5% of the study population 
was fever  with myalgia  and 93.6% cases  come under  the category  of 
dengue fever and 20% showed the sign of rashes.  
The  IgM antibody  study  by  both  spot  ELISA and  IgM capture 
ELISA revealed that 12% were positive for IgM antibodies and 11.2% of 
these  positives  presented  with  dengue  fever  and  0.8% presented  with 
Dengue haemorrhagic fever.   
The IgM positive samples,  inoculated in suckling mice  revealed 
that 10 out of 15 (66%) brain tissues demonstrated dengue virus.  
The confirmation of dengue virus,  in the brain materials was done 
by HA technique showing titres ranging from 80 to 320.  By RT- PCR,  4 
out  of  10  IgM  positive  inoculated  brain  samples  (40%)  showed  the 
amplifications of 511bp C-Pre M- region of dengue virus.  By single tube 
multiplex PCR analysis employing dengue sero type specific amplimers, 
all  these 4 samples revealed 290 bp amplicons,  denoting that this was 
dengue sero type 3.  
CONCLUSION
The study of  prevalence of  dengue sero type in Madurai  by 
molecular methods revealed the following:  
 Dengue cases were common during January 2006 – April  2006, 
due to the unusual rains in December 2005 and March 2006.
 More number of males in the age group 0 – 15 years were affected.
 The commonest  symptom demonstrated  was fever  with  myalgia 
and commonest sign was rashes.
 The spot IgG / IgM and IgM capture ELISA revealed that 12% of 
the affected were positive for IgM antibodies.
 Dengue virus antigen was prepared from the brain of the suckling 
mice by inoculating the IgM positive samples and the antigen titre 
was confirmed by HA technique taking into account 80 – 320 as 
the range of the titre value.  
 These isolated viruses were subjected to RT-PCR and 40% of them 
showed  amplification  of  511  C-Pre  M-  region  confirming  the 
presence of dengue virus.
 The  sero  type  of  dengue  virus  was  found  out  by  single  tube 
multiplex  PCR  analysis  employing  dengue  sero  type  specific 
amplicons demonstrating 290 bp amplicons suggestive of dengue 
sero type 3.    
 In the present study dengue 3 seems to be a emerging infection in 
Madurai population, because since 1986 the arboviral laboratory of 
Madurai Medical College demonstrated only dengue 2 in Madurai 
population.   The common symptom observed was dengue fever, 
now another  sero type is  emerging and there is  a  possibility  of 
dengue haemorrhagic fever and dengue shock syndrome.  So the 
clinicians must  be aware of this fact,  if  any haemorrhagic  fever 
occurs they should keep the fact in mind of dengue in treating these 
cases.  
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PROFORMA
Case Investigation Form
                                            Date:
Patient’s Name:        Patient’s I.D. No.:
      Age / Sex:
Father’s / Husband’s Name:
Address:  Epidemic / Non-Epidemic
Date of on set of illness:
Date of hospitalization:
Occupation:
Clinical signs & symptoms (with duration)
Treatment History:
Results of previous investigations (if any):
Any other relevant information:
Specimen details:
Nature of specimen (s) Date of collection Investigation required
Details of sender:
Signature: Address of sender:
Name of sender: E-mail:
Fax:
PROFORMA
Laboratory Form
Date:
Patient’s Name:           Patient’s I.D. No.:
Age / Sex:
Laboratory Reference No.: 
Specimen details:
Type of 
Specimen
Date of 
Collection
Date of 
Receipt in 
lab
Type of 
test
Remarks 
(if any)
Result
Interpretation:
Details of Investigator:
Name:
Signature
Telephone No.:
Address:
ANNEXURE - I
PREPARATION OF REAGENTS
I. Borate Saline pH 9.0
1.5M NaCl - 160 ml
0.5M H3BO3- 200 ml
1N NaOH - 47 ml
Add double D.W. to make 2 litre, pH 9.0 (if pH is not 9.0 then add 0.5M 
H3BO3or IN NaOH to adjust)
 
II. 0.4% percent Bovine Albumin in Borate Saline (BABS) pH 9.0
Bovine Albumin - 4.0 gm
Borate Saline pH 9- 100 ml
Keep overnight in cold and adjust pH to 9.0 with 1M NaOH. Take 100 ml 
of this solution and add to 900 ml of borate saline solution, pH 9.0.
III. 25% Percent Kaolin in Borate Saline pH 9.0
Kaolin (acid washed) - 25 gm
Borate Saline pH 9.0 - 100 ml
Stir Borate Saline on magnetic stirrer and add Kaolin powder slowly till 
uniform suspension is obtained.
IV. 0.9% % NaCl
NaCl - 9 gm
Double distilled water (DDW) - 1000 ml
Autoclave at 15 Ibs for 15 minutes. 
V. Acid Citrate Dextrose (ACD)
Sodium Citrate - 11.26 gm
Citric Acid - 4.0 gm
Dextrose - 11.0 gm
DDW - 500 ml
Autoclave at 15 Ibs for 10 minutes.
VI. Dextrose Gelatin Veronal
A. Veronal (Diethyl barbituric acid) - 0.580 gm
      Gelatin - 0.600 gm
                Hot D.D.W. -    250 ml
B. Sodium Barbitone - 0.380 gm
     MgSO47H2O - 0.120 gm
               CaCl2 (anhydrous) - 0.020 gm
     NaCl -  8.5 gm
               Dextrose - 10.0 gm
               Merthiolote - 0.1 gm
     D.D.W - 750 ml
Mix A and B solutions.  Autoclave at 10 Ibs for 10 minutes.
VIII. Preparation of Reagents
Collection and Washing of goose RBC
Collection of RBC
Goose RBC are collected under sterile condition.  Take 125 ml of DGV 
in a 250ml flask.
1. Take 10 ml ACD in a sterile tube.
2. Withdraw 7.5 ml ACD in to 50ml syringe fitted with a 20 gauze 
needle.
3. Collect 50ml goose blood from the wing or jugular vein.
4. Remove needle from syringe and transfer blood from syringe to 
flask with DGV.
5. Mix well.
6. Store at 4OC ( can be kept for up to 2 weeks ).
Washing of RBC
1. Centrifuge  required quantity  of  RBC suspension  in  a  graduated 
centrifuge tube for six minutes at 2000 RPM.
2. Aspirate off the supernatant fluid and buffy layer of WBC with 
Pasteur pipette  attached to  a  rubber bulb without disturbing the 
packed RBC.
3. Add 2.0 ml of normal saline (N.S)
4. Mix gently with Pasteur pipette to resuspend cells and additional 
quantity of N.S. to bring it to be original volume.
5. Centrifuge at room temperature for 3 minutes at 2000 RPM.
6. Repeat step 2,3,4 and 5.
7. Centrifuge at 2000 RPM for 6 minutes.
8. Read volume of packed RBC.
9. Remove supernatant fluid.
10. Add NaCl to make a 10% suspension of RBC and mix.  The cells 
are  ready  for  use  in  HI.  (Use  washed  and  packed  cells  for 
adsorption of sera).
 

BIAS 3 DENGUE IgM / IgG KIT
BIAS 3 DENGUE IgM KIT
SUCKLING MICE SHOWING SYMPTOMS
                   HARVESTING OF BRAIN TISSUES
                    
THERMO CYCLER
GEL DOCUMENTATION SYSTEM
PCR POSITIVE SAMPLES SHOWING BANDS AT 511 bp
L1 : 
Positive Sample
L2 : Positive Sample
L3 : Positive Sample
L4 : Positive Sample
L5 : Negative Control
L6 : Ladder [100 bp]
SINGLE TUBE MULTIPLEX PCR ANALYSIS FOR 
SERO TYPING OF DENGUE VIRUS
                                               L1  L2  L3  L4  L5  L6  L7  
L1         L2       L3         L4       L5        L6
L1- MARKER  
L2- NEGATIVE CONTROL
L3- DENV-3
L4- DENV-3
L5- DENV-3
L6- DENV-3
290bp  DENV-3
                 BIAS 3 IgM / IgG KIT SHOWING IgM POSITIVE
BIAS 3 IgM / IgG KIT SHOWING IgG POSITIVE
RESULTS OF HAEMAGGLUTINATION TEST



